Clinuvel Pharmaceuticals Company Description
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders.
In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin.
The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
| Country | Australia |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Lachlan Hay |
Contact Details
Address: 535 Bourke Street Melbourne, 3000 Australia | |
| Phone | 61 3 9660 4900 |
| Website | clinuvel.com |
Stock Details
| Ticker Symbol | CLVLY |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | US1887691038 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Malcolm Bull | Head of Australian Operations and Investor Relations |
| Dr. Azza Hamila | Head of Quality Assurance and Drug Safety |
| David Solomon | Senior Vice President of Regulatory Affairs |
| Claire Newstead-Sinclair C.A. | Company Secretary |